ultima actualización
27 de junio del 2019

10.888.166 visitantes

Novedades de los Journals y web

_Sin Categorizar (1)

Aneurisma periférico (3)

Aneurisma renal (3)

Angioplastia primaria (16)

Angioplatia periférica (1)

Angioplatia coronaria (3)

Aorta (endograft) (4)

Cardiopatía coronaria > Ateromatosa (11)

Cardiopatía coronaria > Otras (7)

Cardiopatías congénitas (3)

Carótida (11)

Drug eluting (20)

The DES Debate: Staying Focused on Our Patients

Stents liberadores de drogas. Un tratamiento para cualquier paciente / lesion?

Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary Lesions: (LONG DES II)

Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions (Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions)

CYPHER® Sirolimus-Eluting Stent Coronary Stent Outperforms Taxus Stent In Head-To-Head Small Vessel Clinical Trial – ISAR-SMART Study Suggests Differences in Late Loss, Restenosis and Target Lesion Revascularization (TLR)

Study Results Indicate The CYPHER® Sirolimus-Eluting Coronary Stent May Reduce Re-Blockage And Chances Of Major Side Effects In Patients With Complex Coronary Lesions

Paclitaxel-eluting stents for the treatment of chronic total coronary occlusions: A strategy of extensive lesion coverage with drug-eluting stents

DES: Technique still matters

Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts

Drug eluting stents for everyone and everything?

IVUS Insights from Drug-Eluting Stent Trials

Drug eluting stents are “not the be all and end all”

Do drug eluting stents impact on mortality?

There are still unresolved issues in Drug-Eluting Stents

ARTS II: Drug-eluting stents as effective as bypass surgery

TAXUS V: Stent Loses Some Luster in Complex Lesions

Drug-eluting stents for in-stent restenosis

Pronostico similar entre los pacientes con enfermedad de los by pass venosos y de las arterias coronarias nativas tratados con stent liberadores de sirolimus en el TRIAL SECURE

Resultados iniciales luego del implante de stents liberadores de sirolimus en pacientes con síndromes coronarios agudos

Cual es la "situación" de la reestenosis en el 2002?

Embolización (3)

Embolización renal (1)

Extracción de cuerpo extraño (2)

Farmacología (hemodinamia) (8)

Imagenología cardíaca (3)

Insuficiencia cardíaca (2)

Material de contraste (2)

Miembros inferiores (8)

Miocardiopatías (4)

Otros (2)

Renales (5)

Stenting (7)

Tromboembolismo pulmonar e hipertensión pulmonar (1)

Valvulopatías (6)

Venas (11)

© hemodinamiadelsur.com.ar es desarrollado y mantenido por ASAP Web | Consultoria de sistemas
Acuerdo con los usuarios
Get Adobe Reader Get Adobe Flash Player